Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial

Jia xiang Jin; Varun R Ginde; Stefanie Huhn; Philipp Reichert; Uta Bertsch; Roland Fenk; Britta Besemer; Amelie Boquoi; Roland Schroers; Ivana von Metzler; Mathias Hänel; Christoph Mann; Lisa B Leypoldt; Bernhard Heilmeier; Christof Scheid; Thorsten Peters-Regehr; Igor W Blau; Carsten Müller-Tidow; Steffen Luntz; Tobias AW Holderried; Karolin Trautmann-Grill; Deniz Gezer; Maika Klaiber-Hakimi; Martin Müller; Evgenii Shumilov; Wolfgang Knauf; Christian S Michel; Thomas Geer; Hendrik Riesenberg; Christoph Lutz; Marc S Raab; Niels Weinhold; Martin Hoffmann; Axel Benner; Peter Findeisen; Katja C Weisel; Hans J Salwender; Elias K Mai; Hartmut Goldschmidt

doi:10.1200/JCO-26-01346

. 2026 Jun 8;44(20):1955. doi: 10.1200/JCO-26-01346

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial

Jia xiang Jin, Varun R Ginde, Stefanie Huhn, Philipp Reichert, Uta Bertsch, Roland Fenk, Britta Besemer, Amelie Boquoi, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa B Leypoldt, Bernhard Heilmeier, Christof Scheid, Thorsten Peters-Regehr, Igor W Blau, Carsten Müller-Tidow, Steffen Luntz, Tobias AW Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Evgenii Shumilov, Wolfgang Knauf, Christian S Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc S Raab, Niels Weinhold, Martin Hoffmann, Axel Benner, Peter Findeisen, Katja C Weisel, Hans J Salwender, Elias K Mai, Hartmut Goldschmidt, for the German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators

PMCID: PMC13340446 PMID: 42258800

The article by Jin et al titled “Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial” (J Clin Oncol 10.1200/JCO-25-02957) was published online May 21, 2026, with errors.

In Figure 1B, the inset text read “Log-rank adjusted P < .001” but should have read “Global log-rank adjusted P < .001.”

In Figure 2B, the “Concordant” heading was on the left side of the figure, and the “Discordant” heading was on the right side of the figure. These positions were reversed and should have shown “Discordant” on the left side of the figure and “Concordant” on the right side of the figure.

This has been corrected as of June 8, 2026. The authors apologize for the errors.

PERMALINK

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial

Jia xiang Jin, MD

Varun R Ginde, MSc, MEng

Stefanie Huhn, PhD

Philipp Reichert, PhD

Uta Bertsch, MD

Roland Fenk, MD

Britta Besemer, MD

Amelie Boquoi, MD

Roland Schroers, MD

Ivana von Metzler, MD

Mathias Hänel, MD

Christoph Mann, MD

Lisa B Leypoldt, MD

Bernhard Heilmeier, MD

Christof Scheid, MD

Thorsten Peters-Regehr, PhD

Igor W Blau, MD

Carsten Müller-Tidow, MD

Steffen Luntz, MD

Tobias AW Holderried, MD

Karolin Trautmann-Grill, MD

Deniz Gezer, MD

Maika Klaiber-Hakimi, MD

Martin Müller, MD

Evgenii Shumilov, MD

Wolfgang Knauf, MD

Christian S Michel, MD

Thomas Geer, MD

Hendrik Riesenberg, MD

Christoph Lutz, MD

Marc S Raab, MD

Niels Weinhold, PhD

Martin Hoffmann, MD

Axel Benner, MD

Peter Findeisen, MD

Katja C Weisel, MD

Hans J Salwender, MD

Elias K Mai, MD

Hartmut Goldschmidt, MD

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases